Despite the association made between sickness and wintertime, many are surprised when they fall ill during the beautiful, warm summer season. While our immune systems do tend to take down viruses with more ease in the summertime, they don’t always win the fight. Thankfully, combatting summer sickness requires a simple, straightforward approach. To protect yourself from getting sick this summer, Dr. Christopher Calapai, D.O. is sharing his simple advice to find a natural fix.
Dr. Calapai is a New York-based Osteopathic Physician, board-certified in family and anti-aging medicine. He suggests the following tips to identify the cause of your ailment and find a natural remedy:
- How clean is your air conditioner?
Air conditioning is a life-saver in the summer heat, but when’s the last time you cleaned your air conditioner? When left uncleaned for long periods of time, air conditioning systems can accumulate a wide array of bacteria that can make you sick. With these little germs being blasted right at you in the cool air, there’s no wonder you may be falling sick in the summer. In fact, studies have indicated a link between using air conditioning and needing to use health services. Not to fear, though—Just make sure to clean your air conditioner regularly and you can enjoy the coolness with much less risk to your health!
- Are you getting a break from your fan or AC?
Constantly being blasted by the cool air has quite the drying effect, not only on your skin, but on your mucus membranes inside your nasal passages. When these are dried out, their ability to defend against infection is greatly weakened, and thus a cold may ensue. Even without infection, the dryness can also cause your body to overproduce mucus in order to compensate, which can mimic cold-like symptoms with congestion and discomfort.
- Are you really even sick?
It’s quite easy to confuse allergies with a cold, especially for those who haven’t previously been subject to the deleterious effects of pollen and other allergens. One easy way to know if you have a virus or if it is merely allergies is by the color of your mucus (assuming you have a runny nose!). A general rule of thumb is that if it is clear and watery, you’re just having allergies, but if it’s more viscous and greenish, it is likely a virus. Another sign that you have allergies and not a cold is that your symptoms remain constant for more than a week to a week and a half, as colds tend to clear up within that time frame.
- How is your sleep schedule?
While our environment plays a substantial role in our health, at the end of the day, colds and other sickness come from viruses and bacteria (usually). The human body’s most fundamental mechanism to ward off these pesky guys is with our immune systems. But how do we show our immune system some love, you may ask? Sleep! But not just any sleep. A consistent, generous number of hours is ideal. Furthermore, the sleep you get with alcohol, marijuana, and other substances in your system is not as revitalizing for your body. As many people drink more in the summer months, pay attention to this, as it may very well be the culprit behind your weakened immune system.
- How clean is clean enough?
Paying attention to cleanliness is even more important in the muggy summer months. First of all, as you may be going out more (and thus touching more things!) in the summer, constantly washing your hands is one of the most reliable ways to stay illness-free. Not only should you keep yourself clean, however, you must also keep your surroundings spick and span. Picking up your clothes and straightening your pillows is not enough in the summer season; it is the smaller bits that pose a more insidious threat. With more air circulating due to AC, all of the microscopic particles have a heightened chance to enter your breathing pathways and make you sick. Not only that, but the warmth also creates an ideal environment for bacteria proliferation, so make sure to wipe down all your surfaces regularly and to stay clean!
About the doctor:
Dr. Christopher Calapai, D.O. is an Osteopathic Physician board certified in family medicine and anti-aging medicine. Proclaimed the "The Stem Cell Guru" by the New York Daily News, Dr. Calapai is a leader in the field of stem cell therapy in the U.S. His stem cell treatments have achieved remarkable results in clinical trials on patients with conditions as varied as Alzheimer's, arthritis, erectile dysfunction, frailty syndrome, heart, kidney and liver failure, lupus, MS and Parkinson's. He has worked with Mike Tyson, Mickey Rourke, Steven Seagal, and Gotham's Donal Logue; and as a medical consultant for the New York Rangers. Connect with him via Twitter @drcalapai or at www.drcal.net.
ProMIS Neurosciences Announces Second Quarter 2018 Results
TORONTO and CAMBRIDGE, MA, Aug. 14, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2018.
"Over the first half of 2018, we focused on three key priorities to advance our business," stated ProMIS Executive Chairman, Eugene Williams. "First, to continue to push toward our goal of initiating the first clinical trial of PMN310 in the second half of 2019; second, to differentiate the oligomer selectivity of PMN310 as best in class profile for the treatment of Alzheimer's disease (AD) versus other amyloid-beta directed therapies in development; and third, to expand our portfolio by developing therapeutic antibodies targeting toxic oligomers of alpha-synuclein for Parkinson's disease (PD) and toxic aggregates of Tar-DNA binding protein (TDP43) for ALS. We are pleased to be on target to meet our objectives for the year and look forward to communicating our accomplishments."
Recent Corporate Highlights
- On May 1, we announced completion of a private placement of 19,306,668 common share units at a price of $0.375 per unit, for gross proceeds of approximately $7,240,000. Each unit consisted of one common share and one-half of a common share purchase warrant. Each whole warrant is exercisable into one common share at a price of $0.48 per share for a 60-month exercise period, subject to earlier expiry on 30 days' notice if, at any time after four months from closing, the 20-day volume-weighted average trading price of the Company's common shares is greater than CDN$1.00. Net proceeds from the private placement will be used for working capital and general corporate purposes.
- During the second quarter of 2018, we received proceeds of $1,550,204 related to the exercise of common stock warrants and stock options. The warrants were exercisable at $0.17, $0.20 and $0.30.
- On April 10, we announced publication of a peer reviewed scientific paper describing a novel target on toxic oligomers of amyloid-beta in AD.
- On June 12, we announced the initiation of producer cell line development for PMN310, our lead therapeutic antibody candidate for treatment of AD. Selexis, SA will carry out this critical first step in the manufacturing of antibody therapeutics using their proprietary Selexis SUREtechnology Platform™.
- On June 26, we announced that our unique discovery platform generated potential new antibody therapeutic candidates targeting toxic oligomers implicated in the development and progression of PD and ALS.
- On June 28, we announced results of the Annual Meeting of Shareholders, whereby all of the resolutions announced in the Management Proxy Circular and placed before the Meeting were overwhelmingly approved by the shareholders.
Financial Results
Results of Operations – Three months ended June 30, 2018 and 2017
The net loss for the three months ended June 30, 2018 was $2,214,861, compared to a net loss of $1,903,396 for the three months ended June 30, 2017. The increased loss in the current period reflects the costs associated with operating the Company's AD therapeutics program, increased contract research and consultant salaries and associated costs, supporting its patent portfolio and general corporate expenditures.
Research and development expenses for the three months ended June 30, 2018 were $1,531,075, as compared to $1,132,258 in the three months ended June 30, 2017. Costs were higher in the current period due to higher research program costs for the AD therapeutics program, recruiting expenses and higher costs to support its patent portfolio, offset by lower stock-based compensation.
General and administrative expenses for the three months ended June 30, 2018 were $683,786, as compared to $768,696 in the three months ended June 30, 2017. The decreased in expenditures in the current period reflect reduced investor relations expenses and foreign exchange expense, offset by higher consultant salaries and associated costs, other professional fees, and stock-based compensation.
Results of Operations – Six months ended June 30, 2018 and 2017
The net loss for the six months ended June 30, 2018 was $3,771,733, compared to a net loss of $3,275,599 for the six months ended June 30, 2017. The increased loss in the current period reflects the costs associated with operating the Company's AD therapeutics program, increased contracted research and consultant salaries and associated costs, supporting its patent portfolio and general corporate expenditures.
Revenues for the six months ended June 30, 2018 and 2017 were nominal and relate to legacy technologies.
Research and development expenses for the six months ended June 30, 2018 were $2,229,082, as compared to $1,851,360 in the six months ended June 30, 2017. Costs are higher in the current period due to higher research program costs for the AD therapeutics program, recruiting expenses and higher costs to support its patent portfolio, offset by lower stock-based compensation.
General and administrative expenses for the six months ended June 30, 2018 were $1,542,656, as compared to $1,420,056 in the six months ended June 30, 2017. The increased expenditures in the current period reflect increased consultant salaries and associated costs and higher stock-based compensation, offset by foreign exchange gains.
Outlook
The Company plans to further advance its AD portfolio, with a focus on development of PMN310 for clinical trial initiation in the second half of 2019. Based on the highly selective binding of PMN310 to the toxic Aβ oligomers and lack of off-target binding to non-toxic forms of Aβ (monomer, plaque), the ProMIS AD program will continue to develop data further supporting potential best in class safety and efficacy versus other Aβ-directed therapies currently in development.
Finally, using its unique technology platform, we will advance work to identify and validate selective antibody therapies for the toxic oligomers of alpha synuclein in PD and TDP43 in ALS, with a view to partnering these assets.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
Future Farm Closes on Acquisition of 50% Interest in Cepg Consulting and Design Inc.; now Ready to Apply for a Dealer License in Canada
VANCOUVER, Aug. 14, 2018 /CNW/ - Future Farm Technologies Inc. (the "Company" or "Future Farm") (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that it has completed its acquisition of a 50% interest in CEPG Consulting and Design Inc. ("CEPG") of St. John's, Newfoundland. CEPG will participate in the cannabis and hemp breeding program under the previously announced joint venture between Future Farm and Rahan Meristem Ltd. ("Rahan"), a world renowned global agro-biotechnology company based in Israel. The joint venture will operate out of both an existing building to be transferred to CEPG by Snellen Holdings (1994) Co. Ltd. ("SHC") and 6,000 square feet of newly constructed laboratories.
CEPG is a Canadian corporation which, until the closing of Future Farm's acquisition of 50% ownership, was wholly owned by SHC, also based in St. John's. SHC has been developing controlled environment plant growth systems since 1981.
CEPG will apply for a dealer license from Health Canada, which will enable research and development to begin on the growth of cannabis plants. Once licensed, the R&D facility will use state-of-the-art controlled environment equipment and techniques to create a research hub for the Rahan and Future Farm JV, which is expected to create valuable IP to be sold or licensed worldwide. The joint venture will develop, own and utilize Rahan's proven and proprietary technology to mass-produce elite new strains of marijuana to fit various profiles required of the medical and legal use of this highly valuable and beneficial plant.
"Now that we are 50% partners with Future Farm, we can fast-track the build-out of our lab space," comments Chris Snellen, President of CEPG. "In the meantime, we hope to outsource initial analytical and tissue culture work to Memorial University of Newfoundland and even partner with them on several R&D projects."
As part of the JV, Rahan shall be responsible for providing the know-how and technology, as well as management and operation of the breeding program.
"We are delighted to continue the path that Chris and CEPG have forged over the years in St. John's," says Bill Gildea, CEO of Future Farm. "The relationships that Chris has made will streamline the process of getting the R&D facility up and running so that we can get down to the business of developing elite strains of cannabis and hemp with our partners at Rahan."
In consideration for the acquisition, SHC received 483,871 shares of Future Farm common stock and a cash payment of CAD$71,780. In addition, Mr. Snellen received a cash payment of CAD$50,000.
On behalf of the Board,
Future Farm Technologies Inc.
William Gildea, Chairman & CEO
About Snellen Holdings:
Snellen Holdings and CEPG (controlled environment plant growth) are founding shareholders of Spot Therapeutics Inc. CEPG designed Spot's 40,000 sq. ft. medical marijuana production facility in Fredericton New Brunswick. CEPG, then a wholly owned Subsidiary of Snellen Holdings was incorporated to be Spot's horticulture department. Shortly after Spot received their 'letter to build' approval from Health Canada, Canopy Growth Corporation bought Spot. Future Farm is now a 50% owner of CEPG.
About Future Farm Technologies Inc.
Future Farm is a Canadian company with holdings throughout North America including California, Massachusetts, Florida, Maine, Puerto Rico and Newfoundland. The Company's mission is to advance sustainable agriculture through production of wholesale and retail cannabis products, including hemp. As a leader in its field, Future Farm is committed to using only the highest quality processes and products. Towards this goal, the Company acquires or partners with licensed cannabis operators, and acquires or develops leading technologies in cannabis production, breeding, genetics, and Controlled Environment Agriculture (CEA). Future Farm's scalable, indoor CEA systems utilize minimal land, water and energy resources. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
SOURCE Future Farm Technologies Inc.
MYM Engages Tourism Management Expert to Develop Concept for CannaCentre in Weedon, Quebec
VANCOUVER, Aug. 14, 2018 /CNW/ - MYM Nutraceuticals Inc., (CSE: MYM)(CSE: MYM.CN)(MYM.CN) (the "Company" or "MYM") is pleased to announce it as engaged well-known tourism and recreational expert, Sylvain Audet, to develop the concept of the CannaCentre in Weedon, QC. The CannaCentre is associated with the Company's 1.5 million square foot medical cannabis greenhouse complex currently under construction in Weedon, Quebec. The CannaCentre will host a research centre, a training facility, an auditorium for cultural and scientific activities, a hotel, a restaurant, a medical cannabis interpretation centre and a medical clinic.
Mr. Audet will work in close collaboration with the Sherbrooke Historical Society to develop the concept of the medical cannabis museum as part of the CannaCentre. Mr. Audet is tasked with identifying the primary, indirect and complementary clientele targets, to suggest services and activities complementary to the project's infrastructure and evaluate the profitability of the overall project.
"The addition of Sylvain Audet provides the project with the expertise for a harmonious tourism and cultural development," said Rob Gietl, CEO of MYM. "Mr. Audet's expertise will allow the region to offer a world-class tourism product that is in line with the needs of the local population."
Mr. Audet's experience includes positions with high-end hotels and resorts, regional organizations promoting tourism and ski resorts in the Eastern Townships. Mr. Audet has more than twenty-five years-experience as a recreational tourism consultant for several companies and regional organizations in Canada. He has acquired extensive expertise in tourism brand development, financial benchmarking analysis, marketing research and business plan development in several recreational tourism fields.
Mr. Audet is currently an instructor at the Université du Quebec à Montreal (UQAM) in the institution's Hospitality and Tourism Management program. Mr. Audet holds a Master of Business Administration (MBA) from Université Laval (Quebec City) and a Bachelor of Business Administration (BAA) in Management and Tourism Intervention from UQAM. Mr. Audet is currently working on a PhD in Business Administration (DBA) at the Heriot-Watt University's Edinburgh Business School (Scotland).
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that are anticipated to have over 1.5 million square feet of production space. MYM is also a shareholder in two additional cannabis production projects in Australia and Colombia. The "Northern Rivers Project" in New South Wales, Australia is expected to have 1.2 million square feet of cannabis production space. In Colombia, MYM partner, Colombia Organica, currently hold a seed to sale license for low THC cannabis and are in the licensing process for the cultivation and production of high THC cannabis extracts. Plans are underway for MYM and Colombia Organica to build a cannabis production facility in the region. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
http://www.mym.ca
Keep up to date with MYM on our social media channels:
Twitter: @mymnutra
Facebook: @mymnutra
Instagram: @mymnutra
Linkedin: @mymnutra
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on http://www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
SOURCE MYM Nutraceuticals Inc.
9/11 Heroes Run National Series to Host Paralympic Wounded Warrior on Running Challenge
WASHINGTON, D.C. — Travis Manion Foundation will host the 11th Annual 9/11 Heroes Run 5K Race Series throughout the month of September, in more than 50 locations across the country and around the world. The race series will unite the community to remember the nearly 3,000 lives lost on 9/11, as well as to honor our veterans, military, and first responders who serve our country and our communities.
This year’s race series will see a special guest at select locations, where United States Marine veteran and Paralympic athlete Rob Jones will be running the 5K as part of a challenge that will see him compete in nine 9/11 Heroes Runs across the country. The locations Rob will participate at include Tempe, AZ on 9/1; Charleston, SC on 9/8; Pennsauken, NJ on 9/9; West Chester, PA on 9/9; a Virtual Run/Ruck on 9/11; Lithia, FL on 9/15; Atlanta, GA on 9/16; Doylestown, PA on 9/23, and New York City on 10/7. The Rob Jones 9/11 Heroes Run Challenge is proud to have support from Comcast/NBC Universal, who is dedicated to providing veterans with opportunities to thrive in their post-military lives through focusing on their strengths and passions, career advancement, and service to the community.
After being injured during his second tour of active duty in Iraq in 2008, Rob undertook a journey not only to rehabilitate, but to excel as an athlete with the goal of bringing awareness to the matters of all veterans and raising money in support of various veterans’ organizations. In 2012, Rob won a bronze medal with Oksana Masters in rowing in the 2012 Summer Paralympics and subsequently came in 4th place in the 2013 World Rowing Championships. In the fall of 2017, Rob undertook a challenge that would garner international attention - he completed 31 marathons in 31 days in 31 different cities across the globe in support of his mission to raise awareness for veteran organizations in the U.S., England, and Canada. Rob’s continued passion for supporting veterans and giving back to his community led him to Travis Manion Foundation, where he volunteers as a Character Does Matter Mentor to the next generation of leaders.
The 9/11 Heroes Run 5K series was inspired by Marine 1st Lt. Travis Manion, who was killed by a sniper in Iraq in April 2007 as he selflessly protected his battalion. Before his final deployment, Travis visited Rescue One in NYC—famous for losing almost all of their men on 9/11—and returned home with deeper passion about why he was fighting in Iraq. At its heart, the 9/11 Heroes Run is a tribute to a personal commitment to never forget the heroes of that day. Now in its 11th year, the 9/11 Heroes Run national race series will be held in more than 50 locations across the country and around the world, and is expected to draw over 60,000 participants. As part of the marketing campaign for the race series, TMF has released a video to inspire runners and walkers of all ages to participate, which can be seen here.
“During this divisive time in our country, I’m in awe at how so many communities across the country and around the world will put differences aside and coming together to honor all those touched by the events of September 11th, 2001.” said Ryan Manion, President of Travis Manion Foundation. “I’m equally moved by the amazing challenge that Rob Jones has taken on to represent what it means to live by ‘If Not Me, Then Who…’ and to be an inspiration for everyone. We challenge all Americans to join us this September, to ensure our future generations never forget the sacrifices of our veterans, active duty military, first responders, and civilians who were affected by the attacks on 9/11 and in the wars since.”
For more information or to register, visit www.911heroesrun.org
About Travis Manion Foundation: Travis Manion Foundation (TMF) unites communities to strengthen America's national character by empowering veterans and families of fallen heroes to develop and lead future generations. In 2007, 1stLt Travis Manion (USMC) was killed in Iraq while saving his wounded teammates. Today, Travis' legacy lives on in the words he spoke before leaving for his final deployment, "If Not Me, Then Who..." Guided by this mantra, veterans continue their service, develop strong relationships with their communities, and thrive in their post-military lives by serving as character role models to youth. As a result, communities prosper and the character of our nation’s heroes lives on in the next generation.
The story of 1st Lt. Travis Manion and his Naval Academy brother Lt. (SEAL) Brendan Looney have been publicized in the book Brothers Forever, and additional information about the Foundation can be found at www.travismanion.org.
###
Bugworks Research Inc Raises $9M Series-A Financing to Develop Novel Antibiotics to Fight Superbugs
Series-A funding plus CARB-X award enables Bugworks to take lead asset(s) to clinical trials
BANGALORE, India, Aug. 14, 2018 /CNW/ - Bugworks Research Inc, a biopharma startup based in Bangalore, India and Delaware, USA, designing first-in-class antibiotics announced the completion of a $9M Series-A financing, led by University of Tokyo Edge Capital (UTEC) Japan, with syndication from Acquipharma Holdings, 3ONE4 Capital and other prominent biotech-focussed global angels.
(Logo: https://mma.prnewswire.com/media/730405/Bugworks_Logo.jpg )
Bugworks' novel bacterial topoisomerase inhibitor (NBTI) is highly effective against a very broad spectrum of multi-drug resistant bacterial pathogens. This potent first-in-class antibiotic was designed using ELUDE, Bugworks' proprietary efflux-pump avoidance platform. ELUDE enables the design of novel, differentiated antibiotics to cure hospital, community and bio-threat infections. Bugworks' NBTI is a dual target small molecule inhibitor, with very low potential to create resistant strains, effective against all pathogens on the WHO Critical, High & Medium priority list as well as the CDC identified bio-threat bacterial pathogens.
"The rise of Anti-microbial Resistance (AMR) is an urgent global issue that needs to be tackled on war-footing. Bugworks addresses the AMR crisis by creating a new class of antibiotics targeting all-known classes of multi-drug resistant bacteria. We would like to promote collaborative developments through strong relationship between Bugworks and the Japan Bio Ecosystem for driving global innovation in this field," said Dr. Atsushi Usami, Partner at UTEC. In connection with the Series A financing, Dr. Usami will be joining the Bugworks' Board of Directors.
"CARB-X funds the best science around the world to address drug resistance. We are pleased to see this Series A investment following the CARB-X award," said Kevin Outterson, Executive Director of CARB-X, which has awarded Bugworks up to $6.2M to support the project.
"This financing is yet another strong endorsement of our team and technology as we bring reputed global investors on board to aid our mission of defeating 'superbug' infections," said Dr. Anand Anandkumar, CEO of Bugworks.
Series-A Investment Syndicate
UTEC is a Tokyo-based early-stage VC, with over $500M Asset-Under-Management linked closely with University of Tokyo and other academic institutions. UTEC invests in seed/early-stage startups that solve global issues for humankind using profound science and technology.
Acquipharma Holdings, started by former C-suite Executives from Quintiles Transnational, is a healthcare investment company, with a diverse global portfolio of biotechnology, medical device and healthcare services investments. The group plays a strategic role in leveraging their global expertise in advancing assets through the clinical stage of development.
3one4 Capital is an early-stage venture capital fund based in Bangalore, India. The focus areas include machine-driven actionable intelligence services for the enterprise, enterprise automation, ambient intelligence technologies, fintech, consumer data strategies, media and content development, and health.
Bugworks (www.bugworksresearch.com)
AMR is a global emergency impacting millions across the world, requiring next-generation novel antibiotics. Bugworks with its years of domain experience and through its innovative approaches has an exciting portfolio of broad-spectrum novel antibiotic assets at various stages of discovery and preclinical development.
SOURCE Bugworks Research Inc.
Statement from Neighbourhood Pharmacy Association of Canada
TORONTO, Aug. 13, 2018 /CNW/ - Neighbourhood Pharmacies applauds the Ontario government's announcement by Minister of Finance Vic Fedeli and Attorney General Caroline Mulroney today to launch consultations about how the province will manage cannabis retail and distribution following the federal government's decision to legalize it on October 17, 2018.
We welcome the Ontario government's measured approach to the legalization of recreational cannabis, while maintaining the following guiding principles: protecting kids, ensuring road safety and combatting the illegal cannabis market.
The Ontario government's decision to consult with businesses, health care professionals, municipalities, First Nations and law enforcement prior to the introduction of the private retail model is warmly welcomed by Neighbourhood Pharmacies. Pharmacy is best placed to be a part of the government's model going forward and we look forward to constructively contributing to the consultation process. Our members have the safeguards in place to maintain the integrity of the supply chain with appropriate inventory management and measures to prevent theft and diversion. We also bring the experience needed to identify the potential signs of addiction, including cannabis use disorder. Our top priority is keeping our communities safe.
Neighbourhood Pharmacies members are the most trusted health care providers with expertise and unparalleled training in medication management, combined with the accompanying infrastructure in place to ensure public safety and health. It is important that pharmacy be included in the distribution and dispensing as the new Ontario retail model unfolds, particularly as communities across the country grapple with the opioid crisis. We must take every measure to ensure oversight for medical and recreational consumers by their pharmacist. We maintain our patients' medication records and can ensure potential drug to drug interactions are considered.
About the Neighbourhood Pharmacy Association of Canada:
The Neighbourhood Pharmacy Association of Canada represents the business of pharmacy and advocates for Canada's leading pharmacy brands who deliver high value, quality care to Canadians in all models including chain, banner, long-term care, specialty and independent pharmacies as well as grocery chains and mass merchandisers with pharmacies. Our focus is on improving the delivery of care environment for pharmacy, while fostering the right business conditions for business success. By leveraging the over 10,500 pharmacies conveniently located in every neighbourhood across Canada, we aim to advance sustainable health care for all stakeholders.
SOURCE Neighbourhood Pharmacy Association of Canada
Compelling Bestseller Helps Families Of Missing Children Cope With Unspeakable Grief
Houston, TX, August 13, 2018 ― Four years ago, Marie White's youngest child was abducted, and in that instant, White's family became one of a frightening statistic.
Over two million families in the United States have faced the unthinkable grief of losing a child through divorce, alienation, abduction, human trafficking or drug addiction. Some of those affected by such profound loss break down mentally, suffer from PTSD, become pathologically depressed, or turn to drugs and alcohol. Some even end their suffering through suicide.
White used the pain of her experience to reach out to others who are desperate for answers while their child is gone.
Her compelling book, Strength for Parents of Missing Children: Surviving Divorce, Abduction, Runaways and Foster Care, is a real, how-to guide for surviving the worst case scenario and finding joy and deeper purpose in the midst of pain.
The book features insights from renowned experts, including Dr. Sue Cornbluth, a nationally recognized expert in parenting and childhood trauma; Logan Clarke, one of the top investigators in the world; and Dr. Raymond Mitsch, psychologist and author of the bestselling book, Grieving the Loss of Someone You Love.
Peppered with reflections on her own personal experiences, White fearlessly covers topics like depression, PTSD, reunification and grief in a way that is both informational and inspirational. Woven throughout are Bible verses meant to strengthen, encourage and motivate families of missing children to find hope through their faith in God.
Strength for Parents of Missing Children is a raw, honest account written by a parent who has not only lived it, but is still living it and still managing to thrive in the midst of grief.
In addition to Strength for Parents of Missing Children, author Marie White has written six other books, including Ten Day Bible Study: Standing Firm on God's Word (Zamiz Press, 2017) and Changing Your Life in Just 10 Days: Creating the Life You Were Always Meant to Live (Zamiz Press, 2016). She is also a TEDx speaker, non-denominational Christian missionary, traveler, entrepreneur and reaches over half a million viewers through her YouTube channel, Bible Stories for Adults. She owns Zamiz Press (Za-h meez), a book publishing company.
To learn more, please visit www.MarieWhiteAuthor.com.
Strength for Parents of Missing Children: Surviving Divorce, Abduction, Runaways and Foster Care
Hawaii Way Publishing
ISBN-10: 1945384093
ISBN-13: 978-1945384097
Available everywhere books are sold
###
TIP SHEET:
Suggested interview questions for Marie White:
1. When we think of missing children, we think of kidnapping or abduction. But you say there are other types of missing children. What are these other types?
2. What are parents of missing children going through physically?
3. What are the emotions that parents go through?
4. What can friends and family say to help hurting parents?
5. What are some things people should not say?
6. What three things can you tell parents living through this right now?
7. You're a veteran. How has your military training influenced how you handle this?
8. How has going through this impacted the way you look at life?
Reviews:
Rev. Daniel B. Gilbert, Ph.D., EmPowered Living International Ministries: "Reading this book is a must for all parents, whether a tragedy has happened or not! As a minister and professor, this book has helped me understand the grieving process even more so I can help others. Marie White writes with such compassion from her heart, yet not withholding the truth that individuals and parents must deal with during loss. I highly recommend Marie's book and hope it will help you as it has helped me.”
Marcy Pusey: "I'll start with noting that I am a clinical counselor. While this book is about families of abducted children, I found SO much value for ANYONE who has experienced loss or grief. The author does a great job communicating practical ways of surviving that trauma. I know anyone walking this living tragedy will find strength and companionship on these pages.”
L. Aiello: "As a parent of an alienated child, I appreciated having this situation profiled alongside other serious losses of children. Finding hope and inspiration to carry on is a real challenge when you are separated from your child, no matter what the reason. Marie's book supports parents in all situations where they are struggling with not knowing and not being with their children. Her book is truly a warm blanket on a very cold night!”
Marcie L. Humphrey: "I highly recommend this book to anyone who is going through parental alienation or any other type of parental loss."
People have a love/hate relationship with Burpees (I love to hate them) But, the Burpee is the broccoli of fitness and is packed with some amazing things for your cardio and muscular endurance, as it works all parts of your body and increases your heart rate, with no equipment needed.
Looking for the perfect burpee? With these three variations from Gixo, you can find the one that works for you and get stronger and stronger each day!
Level 1 - Step back into a plank and forward to squat, stand up and raise arms above head.
Choose this progression if you find it challenging to jump back to plank or forward to squat, and you can also use an elevated surface to make things easier as well.
Level 2 - Jump back to plank and forward to squat, jump up and raise arms above head. Choose this progression if you are comfortable to jump back to plank and forward to squat.
Level 3 - Jump back to plank, add a push up, then forward to squat, jump up and raise arms above head. This will give you an extra challenge.
Not only will this challenge make you stronger, but it’s also for a great cause. Gixo will donate $25 per person who complete the challenge to the Women’s Sports Foundation and the end of the month. That’s because only 25% of girls are getting sufficient physical activity to combat the development of chronic disease and enhance quality of life. Gixo is the fitness app that gives users 19 hours of LIVE fitness classes per day. You’ll get instant feedback, personal training and coaching with a community of Teammates there to support you every step of the way. Unlimited memberships start at $14.99 per month with a yearly subscription and $19.99 per month, monthly.
Gixo, the fitness app with 19 LIVE hours of classes per day are starting a Burpee Challenge on August 1st, benefitting the Women’s Sports Foundation. Each day through the app, there will be a daily on-demand Burpee Challenge class to help you build your reps each day - with a live Burpee Bash on August 31st! At the end of the month and they will donate up to $25 per person who completed the challenge, Why $25? Because only 25% of girls are getting sufficient physical activity to combat the development of chronic disease and enhance quality of life.
Available for iphone and android, your audience can try Gixo for seven-days free and monthly memberships start at $14.99/mo for the year (with a one-time payment of $179) and $19.99 month-to-month for unlimited classes that include yoga, cardio, strength and mobility. If you would like to try Gixo for yourself, please let me know and I can set you up with a trial. The Burpee Challenge can be found here - Gixo Burpee Challenge
Sensus Healthcare CEO Joseph C. Sardano Joins BirchBioMed Inc. Board of Directors
VANCOUVER, Aug. 13, 2018 /CNW/ - BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation, today announced the appointment of Joseph C. Sardano to its board of directors.
A recognized leader in the healthcare industry, Mr. Sardano is Chairman of the Board, President and CEO of Sensus Healthcare, Inc. (NASDAQ: SRTS), which specializes in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT). Mr. Sardano's appointment as BirchBioMed's first independent director is effective immediately.
"We are pleased to have Mr. Sardano join us in our innovative and cutting-edge efforts," said BirchBioMed Chairman and CEO Mark Miller. "His expertise in the healthcare industry, coupled with his company's advanced therapies, makes him an excellent addition to our Board. His management and marketing prowess bring a vital level of expertise to our team, as we seek to develop our ground-breaking treatments and get them into the hands of physicians and patients."
Mr. Sardano brings with him more than 30 years of healthcare management and marketing expertise. He has a strong track record of introducing and commercializing new technologies and services in many areas, including electronic brachytherapy, PET and PET/CT, SPECT, MRI, lithotripsy and digital radiography. Prior to his position at Sensus, he held leadership and management roles at CTI Molecular Imaging, GE Medical Systems, Siemens Medial Systems and Toshiba America Medical Systems, to name a few.
"BirchBioMed has the means to provide cost-effective products that will work in conjunction with Sensus' SRT to prevent and/or eliminate scarring," said Sardano. "This is all about creating better products at a lower cost for patients with scars, and especially keloids, and this collaboration will ultimately create more effective options for both doctors and patients moving forward."
BirchBioMed and Sensus teamed up in early 2018 to further research into using its ground-breaking fibrosis-targeted treatments, including FS2, in conjunction with Sensus' SRT.
About BirchBioMed
BirchBioMed Inc. is a biomedical company focused on the commercialization, clinical evaluation and development of proprietary anti-scarring drugs, autoimmune therapeutics/therapies and novel strategies for transplantation. As a University of British Columbia (UBC) spinoff, BirchBioMed holds the exclusive, worldwide pharmaceutical license for two medical therapeutic technologies from UBC, which the university considers to be significant medical breakthroughs in the treatment of scarring and certain autoimmune diseases
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
SOURCE BirchBioMed
